NYSE:ARA - American Renal Associates Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.24 +0.17 (+1.06 %)
(As of 06/19/2018 04:07 AM ET)
Previous Close$16.24
Today's Range$15.86 - $16.40
52-Week Range$9.91 - $24.07
Volume128,011 shs
Average Volume163,767 shs
Market Capitalization$521.27 million
P/E Ratio26.62
Dividend YieldN/A
Beta2.08
American Renal Associates logoAmerican Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2017, it owned and operated 228 dialysis clinics in partnership with 401 nephrologist partners treating approximately 15,600 patients in 26 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ARA
CUSIPN/A
Phone978-922-3080

Debt

Debt-to-Equity Ratio4.63
Current Ratio1.15
Quick Ratio1.10

Price-To-Earnings

Trailing P/E Ratio26.62
Forward P/E Ratio23.20
P/E Growth0.78

Sales & Book Value

Annual Sales$745.11 million
Price / Sales0.71
Cash Flow$1.9333 per share
Price / Cash8.40
Book Value$3.83 per share
Price / Book4.24

Profitability

EPS (Most Recent Fiscal Year)$0.61
Net Income$4.85 million
Net Margins0.60%
Return on Equity16.88%
Return on Assets2.26%

Miscellaneous

Employees4,692
Outstanding Shares32,440,000

American Renal Associates (NYSE:ARA) Frequently Asked Questions

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings Inc (NYSE:ARA) announced its quarterly earnings results on Tuesday, May, 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.02. The company had revenue of $194.67 million for the quarter, compared to analyst estimates of $189.10 million. American Renal Associates had a net margin of 0.60% and a return on equity of 16.88%. The firm's revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.07 earnings per share. View American Renal Associates' Earnings History.

When is American Renal Associates' next earnings date?

American Renal Associates is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for American Renal Associates.

What price target have analysts set for ARA?

2 equities research analysts have issued 12-month price objectives for American Renal Associates' stock. Their forecasts range from $20.00 to $22.00. On average, they anticipate American Renal Associates' share price to reach $21.00 in the next twelve months. View Analyst Ratings for American Renal Associates.

Who are some of American Renal Associates' key competitors?

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the folowing people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 64)
  • Mr. Syed T. Kamal, Founder, Pres & Director (Age 65)
  • Mr. Jonathan L. Wilcox, VP & CFO (Age 44)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 55)
  • Mr. Jason M. Boucher, VP of Fin., Chief Accounting Officer & Treasurer (Age 46)

When did American Renal Associates IPO?

(ARA) raised $161 million in an IPO on Thursday, April 21st 2016. The company issued 7,500,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Has American Renal Associates been receiving favorable news coverage?

News stories about ARA stock have trended somewhat positive recently, according to Accern. Accern ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. American Renal Associates earned a media sentiment score of 0.15 on Accern's scale. They also assigned media headlines about the company an impact score of 46.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are American Renal Associates' major shareholders?

American Renal Associates' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Van Berkom & Associates Inc. (7.97%), Franklin Resources Inc. (2.40%), JPMorgan Chase & Co. (2.40%), BlackRock Inc. (1.95%), OppenheimerFunds Inc. (0.86%) and Dimensional Fund Advisors LP (0.79%). View Institutional Ownership Trends for American Renal Associates.

Which institutional investors are selling American Renal Associates stock?

ARA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Van Berkom & Associates Inc., Citadel Advisors LLC, Altrinsic Global Advisors LLC, Federated Investors Inc. PA, Alambic Investment Management L.P., BlackRock Inc. and Schroder Investment Management Group. View Insider Buying and Selling for American Renal Associates.

Which institutional investors are buying American Renal Associates stock?

ARA stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., JPMorgan Chase & Co., Dimensional Fund Advisors LP, Argent Capital Management LLC, Spark Investment Management LLC, Cambridge Investment Research Advisors Inc., A.R.T. Advisors LLC and Engineers Gate Manager LP. View Insider Buying and Selling for American Renal Associates.

How do I buy shares of American Renal Associates?

Shares of ARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $16.24.

How big of a company is American Renal Associates?

American Renal Associates has a market capitalization of $521.27 million and generates $745.11 million in revenue each year. The company earns $4.85 million in net income (profit) each year or $0.61 on an earnings per share basis. American Renal Associates employs 4,692 workers across the globe.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]


MarketBeat Community Rating for American Renal Associates (ARA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  226
MarketBeat's community ratings are surveys of what our community members think about American Renal Associates and other stocks. Vote "Outperform" if you believe ARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.